跳至主要内容
临床试验/CTRI/2022/02/039978
CTRI/2022/02/039978招募中未知

Randomized controlled trial comparing the efficacy of teriparatide, zoledronate and denosumab in postmenopausal women with type 2 diabetes mellitus at high risk of fragility fractures: a pilot study.

Postgraduate Institute of Medical Education and Research Chandigarh0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Ambulatory type 2 diabetes mellitus postmenopausal females
  • 2. Age more than or equal to 50 years
  • 3. Postmenopausal status for at least 5 years
  • 4. Duration of type 2 diabetes mellitus at least 5 years
  • 5. Baseline eGFR more than or equal to 45 ml/min/1.73 m2
  • 6. Baseline HbA1c 7-10%
  • 7. Baseline BMI more than or equal to 23 kg/m2
  • 8. Prior vertebral (clinical or morphometric), hip, radius, humerus fragility fracture OR
  • 9. Baseline BMD T-score at lumbar spine or femoral neck less than or equal to -2.5 (corrected for T2D) and baseline FRAX score (corrected for T2D) indicating a 10-year probability of hip fracture more than or equal to 2.5% or of major osteoporotic fracture more than or equal to 9%.
  • 10. Those willing to give informed consent

排除标准

  • 1. Type 1 diabetes mellitus or latent autoimmune diabetes in adults, or secondary diabetes mellitus
  • 2. Prior history of use of bone-active therapies (bisphosphonates, teriparatide, denosumab, selective estrogen receptor modulators, hormone replacement therapies, calcitonin)
  • 3. Prior history of glucocorticoid use at a dose more than or equal to 15 mg (prednisolone or equivalent) for more than or equal to 3 months.
  • 4. History of use of pioglitazone, thiazides, or canagliflozin over last 6 months
  • 5. Hyperthyroidism (overt/subclinical) or overt hypothyroidism (detected during baseline screening)
  • 6. History of hypoparathyroidism or primary hyperparathyroidism
  • 7. History of acromegaly
  • 8. History of Addison disease or Cushingââ?¬•s syndrome
  • 9. History of gonadal insufficiency (primary or secondary)
  • 10. History of hypercalcemia (or detected during baseline screening)
  • 11. Elevated hepatic transaminase levels more than or equal to 3 times upper limit of normal (detected during baseline screening)
  • 12. Any solid organ or bone marrow transplant
  • 13. History of any active or past malignancy
  • 14. History of gastrointestinal disorders and malabsorption states, namely, celiac disease (also screened at baseline), inflammatory bowel disease, chronic hepatitis, bowel resection, chronic liver disease, gastrectomy, lactose intolerance
  • 15. History of bone marrow related disorders, namely, leukemia, lymphoma, hemochromatosis, multiple myeloma (also screened at baseline), sarcoidosis, sickle cell anemia, thalassemia, amyloidosis
  • 16. History of rheumatological disorders, namely, rheumatoid arthritis, ankylosing spondylitis, Marfans syndrome, Ehler-Danlos syndrome
  • 17. History of any condition that may affect bone metabolism, namely, Pagetââ?¬•s disease, osteopetrosis, osteogenesis imperfecta, hypophosphatasia
  • 18. History of recent tooth extraction (within 6 months of screening)

研究者

发起方
Postgraduate Institute of Medical Education and Research Chandigarh

相似试验